Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750822 | 1.00 | NPY5R (0.40) | NPY5RDPP4DPP8DPP9ADORA2A | |
| SCHEMBL3745139 | 1.00 | NPY5R (0.40) | NPY5RDPP4DPP8DPP9ADORA2A | |
| SCHEMBL208598 | 0.94 | NPY5R (0.40) | NPY5RADORA2AHSD11B1MEN1ALDH1A1 | |
| SCHEMBL208597 | 0.94 | NPY5R (0.40) | NPY5RADORA2AHSD11B1MEN1ALDH1A1 | |
| SCHEMBL209247 | 0.94 | NPY5R (0.40) | NPY5RADORA2AHSD11B1MEN1ALDH1A1 | |
| SCHEMBL2176405 | 0.90 | DPP4 (0.43) | NPY5RDPP4DPP8DPP9CYP2D6 | |
| SCHEMBL6103837 | 0.84 | NOS3 (0.43) | NPY5RDPP4DPP8DPP9CYP2D6 | |
| SCHEMBL19271810 | 0.84 | NOS3 (0.43) | NPY5RDPP4DPP8DPP9CYP2D6 | |
| SCHEMBL17185334 | 0.83 | — | — | |
| SCHEMBL867932 | 0.82 | NOS3 (0.42) | NPY5RDPP4DPP8DPP9ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904500-A1 | NEW DERIVATIVES OF HEPTAAZAPHENALENE, METHODS FOR OBTAINING THEM, AND THEIR USE AS PROTECTING AGENTS AGAINST UV RADIATION | ISDIN, S.A. (ES) | 2008-04-02 | — | — | EP | claimed |
| WO-2007006807-A1 | NEW DERIVATIVES OF HEPTAAZAPHENALENE, METHODS FOR OBTAINING THEM, AND THEIR USE AS PROTECTING AGENTS AGAINST UV RADIATION | ISDIN, S.A. (ES) | 2007-01-18 | — | — | WO | claimed |
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1830840-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1830841-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1830840-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1830841-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068991-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006068992-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD17B10 | NPY5R 3365/4885DPP4 1332/4885DPP8 1453/4885 |
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD3B1 | NPY5R 3443/4885DPP4 1215/4885DPP8 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.